Food and Drug Administration Commissioner Marty Makary told CNBC that he believes “everything should be over-the-counter” unless a drug is unsafe, addictive or requires monitoring – doubling down on a push that some in the pharmaceutical industry have questioned. In an interview on Wednesday in Washington, D.C., Makary said the FDA’s aims to make changes…
Danaher ‘s days in the portfolio may be numbered. We’re again left disappointed after Danaher’s latest acquisition plan failed to inspire Wall Street. Shares of the life sciences giant lost more than 3.5% following Tuesday’s announcement that the company agreed to buy medtech Masimo for $180 per share in cash, or more than $9.6 billion. Masimo…
Maziar Mike Doustdar, CEO of Novo Nordisk, speaks in the Oval Office during an event about weight-loss drugs at the White House in Washington, DC on November 6, 2025. Andrew Caballero-Reynolds | Afp | Getty Images Novo Nordisk entered 2026 with the momentum of a historic year in more ways than one – but recent…
When Steve Beard took on the role of CEO at higher education firm Adtalem Global Education in 2021, the company was undergoing a significant strategic shift. It had identified gaps in the health-care workforce pipeline, which were expected to grow. That led Adtalem to exit its other education business units and focus solely on health-care education. …
A researcher works in the lab at the Moderna Inc. headquarters in Cambridge, Massachusetts, US, on Tuesday, March 26, 2024. Adam Glanzman | Bloomberg | Getty Images The Food and Drug Administration has refused to start a review of Moderna‘s application for its experimental flu shot, the company announced Tuesday, in another sign of the…
In Florida, a new genetic disease screening program allows parents of newborns to receive free whole genome sequencing at birth, putting the state at the forefront of newborn screening. The five-year pilot program, created in July via the Sunshine Genetics Act, is paid for by a mix of private and state funding, and requires parents…
A box of Wegovy pills arranged at a pharmacy in Provo, Utah, US, on Thursday, Jan. 15, 2026. George Frey | Bloomberg | Getty Images The Food and Drug Administration said Novo Nordisk‘s TV advertisement for its newly launched Wegovy pill for obesity included “false or misleading” claims about the medicine’s abilities and benefits to…
Piotr Swat | Lightrocket | Getty Images Hims & Hers on Saturday said that it will pull its copycat weight-loss pill off the market after sparking controversy and threats of legal action earlier this week. “Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry,” the telehealth…
Albert Bourla, chairman and CEO of Pfizer, speaks at The Wall Street Journal’s Future of Everything Festival in New York City, U.S., May 22, 2024. Andrew Kelly | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive…
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters It’s a tale of two drugmakers in the red-hot obesity drug market. Both Novo Nordisk and Eli Lilly are grappling with lower prices in the U.S., but their 2026 outlooks are diverging sharply: While Novo is bracing for a sales decline,…
